Ezura Y - Search Results

1

Nanogel-based scaffold delivery of prostaglandin E(2) receptor-specific agonist in combination with a low dose of growth factor heals critical-size bone defects in mice.

Kamolratanakul P, Hayata T, Ezura Y, Kawamata A, Hayashi C, Yamamoto Y, Hemmi H, Nagao M, Hanyu R, Notomi T, Nakamoto T, Amagasa T, Akiyoshi K, Noda M. Kamolratanakul P, et al. Among authors: ezura y. Arthritis Rheum. 2011 Apr;63(4):1021-33. doi: 10.1002/art.30151. Arthritis Rheum. 2011. PMID: 21190246 Free article.

2

Unloading induces osteoblastic cell suppression and osteoclastic cell activation to lead to bone loss via sympathetic nervous system.

Kondo H, Nifuji A, Takeda S, Ezura Y, Rittling SR, Denhardt DT, Nakashima K, Karsenty G, Noda M. Kondo H, et al. Among authors: ezura y. J Biol Chem. 2005 Aug 26;280(34):30192-200. doi: 10.1074/jbc.M504179200. Epub 2005 Jun 16. J Biol Chem. 2005. PMID: 15961387 Free article.

3

[Osteopontin and regulation of bone metabolism].

Noda M, Kato N, Ezura Y. Noda M, et al. Among authors: ezura y. Nihon Rinsho. 2005 Oct;63 Suppl 10:605-7. Nihon Rinsho. 2005. PMID: 16279708 Review. Japanese. No abstract available.

4

Runx2 is a target of mechanical unloading to alter osteoblastic activity and bone formation in vivo.

Salingcarnboriboon R, Tsuji K, Komori T, Nakashima K, Ezura Y, Noda M. Salingcarnboriboon R, et al. Among authors: ezura y. Endocrinology. 2006 May;147(5):2296-305. doi: 10.1210/en.2005-1020. Epub 2006 Feb 2. Endocrinology. 2006. PMID: 16455780

5

Osteopontin is associated with nuclear factor kappaB gene expression during tail-suspension-induced bone loss.

Ishijima M, Ezura Y, Tsuji K, Rittling SR, Kurosawa H, Denhardt DT, Emi M, Nifuji A, Noda M. Ishijima M, et al. Among authors: ezura y. Exp Cell Res. 2006 Oct 1;312(16):3075-83. doi: 10.1016/j.yexcr.2006.06.003. Epub 2006 Jun 7. Exp Cell Res. 2006. PMID: 16889770

6

Lack of Schnurri-2 expression associates with reduced bone remodeling and osteopenia.

Saita Y, Takagi T, Kitahara K, Usui M, Miyazono K, Ezura Y, Nakashima K, Kurosawa H, Ishii S, Noda M. Saita Y, et al. Among authors: ezura y. J Biol Chem. 2007 Apr 27;282(17):12907-15. doi: 10.1074/jbc.M611203200. Epub 2007 Feb 20. J Biol Chem. 2007. PMID: 17311925 Free article.

7

Serum osteopontin, an enhancer of tumor metastasis to bone, promotes B16 melanoma cell migration.

Hayashi C, Rittling S, Hayata T, Amagasa T, Denhardt D, Ezura Y, Nakashima K, Noda M. Hayashi C, et al. Among authors: ezura y. J Cell Biochem. 2007 Jul 1;101(4):979-86. doi: 10.1002/jcb.21298. J Cell Biochem. 2007. PMID: 17390343

8

Osteopontin deficiency enhances anabolic action of EP4 agonist at a sub-optimal dose in bone.

Kato N, Kitahara K, Rittling SR, Nakashima K, Denhardt DT, Kurosawa H, Ezura Y, Noda M. Kato N, et al. Among authors: ezura y. J Endocrinol. 2007 Apr;193(1):171-82. doi: 10.1677/joe.1.06917. J Endocrinol. 2007. PMID: 17400814

9

Osteopontin is required for mechanical stress-dependent signals to bone marrow cells.

Ishijima M, Tsuji K, Rittling SR, Yamashita T, Kurosawa H, Denhardt DT, Nifuji A, Ezura Y, Noda M. Ishijima M, et al. Among authors: ezura y. J Endocrinol. 2007 May;193(2):235-43. doi: 10.1677/joe.1.06704. J Endocrinol. 2007. PMID: 17470514

10

PlexinD1 deficiency induces defects in axial skeletal morphogenesis.

Kanda T, Yoshida Y, Izu Y, Nifuji A, Ezura Y, Nakashima K, Noda M. Kanda T, et al. Among authors: ezura y. J Cell Biochem. 2007 Aug 15;101(6):1329-37. doi: 10.1002/jcb.21306. J Cell Biochem. 2007. PMID: 17477353

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

149 results

Search Page